WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Logo (PRNewsfoto/Vanda ...

After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling out the regulatory agency for a “disturbing pattern ...

The notice offers Vanda an opportunity to request a hearing on the matter. Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In ...

Vanda Pharma VNDA has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vanda called the attention of FDA Commissioner Robert Califf to what it termed the “sentiment that the agency avoids public scrutiny of its decisions.” Vanda Pharmaceuticals on Wednesday sent a letter ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...

The FDA met resistance from a three-judge panel Wednesday over its decision to refuse approval of Vanda Pharmaceuticals Inc.’s jet lag disorder drug. At issue in arguments before the US Court of ...